{"id":13521,"date":"2024-05-10T11:06:15","date_gmt":"2024-05-10T09:06:15","guid":{"rendered":"https:\/\/semmelweis.hu\/pharmacology\/?page_id=13521"},"modified":"2025-06-16T13:30:03","modified_gmt":"2025-06-16T11:30:03","slug":"kardio-onkologia-munkacsoport","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/pharmacology\/kutatas\/kardiovaszkularis-es-metabolizmus\/kardio-onkologia-munkacsoport\/","title":{"rendered":"Kardio-onkol\u00f3gia munkacsoport"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Cardio-Oncology and Cardio-Immunology Research Group\" width=\"753\" height=\"424\" src=\"https:\/\/www.youtube.com\/embed\/TkbLlAoHIpY?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<div class=\"responsive-tabs\">\n<h2 class=\"tabtitle\">Projektek<\/h2>\n<div class=\"tabcontent\">\n\n<p><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><b>Gyullad\u00e1sos \u00e9s immunol\u00f3giai folyamatok vizsg\u00e1lata kardiovaszkul\u00e1ris megbeteged\u00e9sekben<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">A kr\u00f3nikus sz\u00edvel\u00e9gtelens\u00e9g progn\u00f3zisa a modern ter\u00e1pi\u00e1s eszk\u00f6z\u00f6k \u00e9s gy\u00f3gyszerek mellett is igen rossz, a betegek mintegy fele a diagn\u00f3zist k\u00f6vet\u0151 5 \u00e9ven bel\u00fcl meghal. A betegs\u00e9g kezel\u00e9se igen nagy terhet r\u00f3 az eg\u00e9szs\u00e9g\u00fcgyi rendszerekre. A sz\u00edvel\u00e9gtelens\u00e9g sz\u00e1mos okb\u00f3l j\u00f6het l\u00e9tre, de kialakul\u00e1sa sor\u00e1n a sz\u00edvizomzat szerkezete \u00e9s funkcionalit\u00e1sa k\u00e1rosodik. Leggyakoribb okok k\u00f6z\u00e9 az iszk\u00e9mi\u00e1s sz\u00edvbetegs\u00e9g, genetikai \u00e9s gy\u00f3gyszer induk\u00e1lta (leggyakrabban tumor ellenes kemoter\u00e1pi\u00e1k) kardiomiop\u00e1ti\u00e1k tartoznak, de aritmi\u00e1k \u00e9s billenty\u0171betegs\u00e9gek is okozhatj\u00e1k a kialakul\u00e1s\u00e1t. Az elt\u00e9r\u0151 etiol\u00f3gia ellen\u00e9re a sz\u00edvel\u00e9gtelens\u00e9g progresszi\u00f3jaban fontos szerepet j\u00e1tszanak mind cellul\u00e1ris (neutrophil granulocit\u00e1k, makrof\u00e1gok, B \u00e9s T limfocit\u00e1k) mind pedig humor\u00e1lis gyullad\u00e1sos folyamatok, gyullad\u00e1skelt\u0151 citokinek, neuropeptidek, \u00edgy az IL-1\u03b2, IL-18 vagy a TNF-\u03b1, melyek jelent\u0151sen fokozz\u00e1k a sz\u00edvizomzat k\u00e1rosod\u00e1s\u00e1t.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-13655 aligncenter\" src=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-400x225.jpg\" alt=\"\" width=\"713\" height=\"401\" srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-400x225.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-1024x576.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-768x432.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-753x424.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas.jpg 1280w\" sizes=\"auto, (max-width: 713px) 100vw, 713px\" \/><\/span><\/p>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">Vizsg\u00e1lataink c\u00e9lja ezen sejtt\u00edpusok \u00e9s a k\u00fcl\u00f6nb\u00f6z\u0151 humor\u00e1lis faktorok ter\u00e1pi\u00e1s modul\u00e1l\u00e1s\u00e1nak vizsg\u00e1lata k\u00fcl\u00f6nb\u00f6z\u0151 sz\u00edvel\u00e9gtelens\u00e9g modellekben \u00e9s <\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>in vitro<\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"> sejtalap\u00fak\u00eds\u00e9rletes rendszereken.<\/span><\/span><\/span><\/p>\n<p><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\"><b>1. Gyullad\u00e1sos folyamatok vizsg\u00e1lata metabolikus betegs\u00e9gekhez (elh\u00edz\u00e1s, cukorbetegs\u00e9g, hiperkoleszterin\u00e9mia, m\u00e1jcirrh\u00f3zis) \u00e9s \u00f6reged\u00e9shez t\u00e1rsul\u00f3 sz\u00edvizom diszfunkci\u00f3 kialakul\u00e1s\u00e1ban <\/b><\/span><\/p>\n<p><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Projektfelel\u0151s: Dr. T\u00f3th Vikt\u00f3ria, Dr. Varga Zolt\u00e1n <\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">A sz\u00edvel\u00e9gtelens\u00e9g a vezet\u0151 hal\u00e1lokok k\u00f6z\u00e9 tartozik vil\u00e1gszerte. Klinikailag k\u00e9t mark\u00e1nsan elk\u00fcl\u00f6n\u00fcl\u0151 form\u00e1ban jelentkezhet a betegs\u00e9g: cs\u00f6kkent ejekci\u00f3s frakci\u00f3val (HFrEF) vagy megtartott ejekci\u00f3s frakci\u00f3val (HFpEF). A sz\u00edvel\u00e9gtelens\u00e9gben szenved\u0151 betegek k\u00f6zel fel\u00e9n\u00e9l HFpEF jelentkezik, azaz az ejekci\u00f3s frakci\u00f3 megtartott. Ezek a betegek \u00e1ltal\u00e1ban id\u0151sek \u00e9s gyakran t\u00f6bb t\u00e1rsbetegs\u00e9gben szenvednek (pl.: diab\u00e9tesz, elh\u00edz\u00e1s, hiperkoleszterin\u00e9mia). Sok esetben a betegek nem reag\u00e1lnak j\u00f3l a HFrEF kezel\u00e9se sor\u00e1n haszn\u00e1lt gy\u00f3gyszerekre (digit\u00e1lisz, ACE g\u00e1tl\u00f3, \u03b2-blokkol\u00f3), emiatt igen jelent\u0151s az ezen a ter\u00fcleten t\u00f6rt\u00e9n\u0151 gy\u00f3gyszerfejleszt\u00e9s. A HFpEF-et jellemzi ezen fel\u00fcl a magas mortalit\u00e1s (65% -os 5 \u00e9ves mortalit\u00e1s). <\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">HFpEF kialakul\u00e1s\u00e1nak molekul\u00e1ris mechanizmusa kev\u00e9ss\u00e9 ismert, jobb meg\u00e9rt\u00e9se a betegs\u00e9g kimenetel\u00e9nek jav\u00edt\u00e1sa \u00e9rdek\u00e9ben viszont elengedhetetlen. Felt\u00e9telezhet\u0151, hogy a kardi\u00e1lis diszfunkci\u00f3hoz hozz\u00e1j\u00e1rulhat egy sziszt\u00e9m\u00e1s gyullad\u00e1sos \u00e1llapot, azonban ennek oki szerepe m\u00e9g nem bizony\u00edtott. Jelenlegi ismereteinket tov\u00e1bb korl\u00e1tozza ezen komplex betegs\u00e9g \u00e1llatk\u00eds\u00e9rletes modellez\u00e9s\u00e9nek neh\u00e9zs\u00e9ge.<\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">C\u00e9lunk, olyan \u00faj \u00e1llatmodellek kifejleszt\u00e9se \u00e9s vizsg\u00e1lata, melyek a HFpEF transzl\u00e1ci\u00f3s vizsg\u00e1lat\u00e1t lehet\u0151v\u00e9 teszik.<\/span><\/p>\n<p><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Elsaj\u00e1t\u00edthat\u00f3 technik\u00e1k:<\/span><\/p>\n<ul>\n<li><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">munka k\u00eds\u00e9rleti \u00e1llatokkal,<\/span><\/li>\n<li><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">hisztol\u00f3giai technik\u00e1k, immunohisztok\u00e9mia,<\/span><\/li>\n<li><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">RNS \u00e9s feh\u00e9rje munk\u00e1k \u2013 Western blot, qRT-PCR<\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\"><i>Referenci\u00e1k: <\/i><\/span><\/p>\n<ol>\n<li>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><i>Valenta I*, Varga ZV*, Valentine H, Cinar R, Horti A, Mathews WB, Dannals RF, Steele K, Kunos G, Wahl RL, Pomper MG, Wong DF, Pacher P, Schindler TH. Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach. JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):320-332. [IF: 10.189] *-megosztott els\u0151szerz\u0151s\u00e9g<\/i><\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><i>Varga ZV, Kupai K, Sz\u0171cs G, G\u00e1sp\u00e1r R, P\u00e1l\u00f3czi J, Farag\u00f3 N, Zvara A, Pusk\u00e1s LG, R\u00e1zga Z, Tiszlavicz L, Bencsik P, G\u00f6rbe A, Csonka C, Ferdinandy P, Csont T.: MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative\/nitrative stress and subsequent dysfunction in the heart. J Mol Cell Cardiol. 2013. 62:111-21. [IF: 5.218]<\/i><\/span><\/span><\/p>\n<\/li>\n<\/ol>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\"><b>2. Kardio-onkol\u00f3gia \u00e9s Onko-kardiol\u00f3gia<\/b><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Projektfelel\u0151s: Gergely Tam\u00e1s, Nabil Sayour, Kov\u00e1cs Tam\u00e1s, Dr. Varga Zolt\u00e1n<\/span><\/p>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">A sz\u00edv- \u00e9s \u00e9rrendszeri, valamint a daganatos megbeteged\u00e9sek gyakran k\u00e9z a k\u00e9zben j\u00e1rnak, \u00e9s egyazon betegben alakulnak ki. A k\u00e9t betegs\u00e9gcsoport a vil\u00e1gon bek\u00f6vetkez\u0151 \u00f6sszes hal\u00e1leset k\u00f6zel fel\u00e9\u00e9rt felel\u0151s, \u00edgy nem meglep\u0151, hogy kit\u00fcntetett figyelem \u00f6vezi a k\u00e9t s\u00falyos k\u00f3r\u00e1llapot egyidej\u0171 el\u0151fordul\u00e1s\u00e1t. A kardiovaszkul\u00e1ris \u00e9s onkol\u00f3giai betegs\u00e9gek k\u00f6z\u00f6s rizik\u00f3faktorokkal rendelkeznek, hasonl\u00f3 patomechanizmusokon kereszt\u00fcl alakulhatnak ki, de bizonyos esetekben k\u00f6z\u00f6s genetikai h\u00e1tt\u00e9rrel is rendelkezhetnek, nem besz\u00e9lve az alkalmazott kezel\u00e9sek esetleges mell\u00e9khat\u00e1sair\u00f3l. Ezzel foglalkozik a <\/span><span style=\"font-family: Times New Roman, serif\"><u><b>kardio-onkol\u00f3gia<\/b><\/u><\/span><span style=\"font-family: Times New Roman, serif\"> tudom\u00e1nyter\u00fclete.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Az elm\u00falt \u00e9vtizedekben jelent\u0151s el\u0151rel\u00e9p\u00e9s t\u00f6rt\u00e9nt a daganatellenes ter\u00e1pi\u00e1kban. Az immunter\u00e1pi\u00e1k bevezet\u00e9se sz\u00e1mottev\u0151en jav\u00edtotta az onkol\u00f3giai betegek t\u00fal\u00e9l\u00e9s\u00e9t. Az immunellen\u0151rz\u0151pont-g\u00e1tl\u00f3k (ICI) az immunter\u00e1pi\u00e1knak a leggyakrabban alkalmazott t\u00edpus\u00e1t k\u00e9pviselik. Ezek a monoklon\u00e1lis antitestek az immunsejtek aktiv\u00e1l\u00f3d\u00e1s\u00e1nak tumor \u00e1ltali g\u00e1tl\u00e1s\u00e1t ford\u00edtj\u00e1k vissza \u00e9s \u00edgy egy fokozott adapt\u00edv immunv\u00e1lasz seg\u00edts\u00e9g\u00e9vel el\u0151seg\u00edtik a r\u00e1kos sejtek elpuszt\u00edt\u00e1s\u00e1t. Jelent\u0151s\u00e9g\u00fcket mutatja, hogy a CTLA-4 \u00e9s PD-1 receptorok felfedez\u00e9s\u00e9\u00e9rt James P. Allison \u00e9s Tasuko Honjo 2018-ban \u00e1tvehett\u00e9k az orvosi Nobel-d\u00edjat.<\/span><\/p>\n<p align=\"center\">\u00a0<\/p>\n<p align=\"center\"><span style=\"font-size: 14pt\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-13657 aligncenter\" src=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_tcells-400x158.png\" alt=\"\" width=\"684\" height=\"270\" srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_tcells-400x158.png 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_tcells-1024x406.png 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_tcells-768x304.png 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_tcells-753x298.png 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_tcells.png 1212w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Az immunrendszer aktiv\u00e1l\u00e1sa a fent eml\u00edtett m\u00f3don nem specifikus, az ICI-ter\u00e1pia a nem daganatos sz\u00f6vetekben is az immunsejtek t\u00falaktiv\u00e1l\u00f3d\u00e1s\u00e1t v\u00e1lthatja ki, ez\u00e1ltal immunkapcsolt mell\u00e9khat\u00e1sokhoz (irAE) vezethetnek. A legritk\u00e1bban jelentkez\u0151, viszont egyben legs\u00falyosabb mell\u00e9khat\u00e1s a sz\u00edvizomgyullad\u00e1s \u00e9s a sz\u00edvel\u00e9gtelens\u00e9g.<\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">F\u0151 c\u00e9lkit\u0171z\u00e9s\u00fcnk a ritka mell\u00e9khat\u00e1sk\u00e9nt megjelen\u0151 sz\u00edvizomk\u00e1rosod\u00e1s h\u00e1tter\u00e9ben \u00e1ll\u00f3 folyamatok megismer\u00e9se. Ez\u00e1ltal \u00faj diagnosztikus \u00e9s ter\u00e1pi\u00e1s c\u00e9lpontok azonos\u00edt\u00e1sa, melyek befoly\u00e1sol\u00e1s\u00e1val cs\u00f6kkenteni lehet az immunellen\u0151rz\u0151pont-g\u00e1tl\u00f3k k\u00e1ros mell\u00e9khat\u00e1s\u00e1nak el\u0151fordul\u00e1s\u00e1t, s\u00falyoss\u00e1g\u00e1t. K\u00fcl\u00f6n\u00f6s hangs\u00falyt fektet\u00fcnk a csecsem\u0151mirigyben aktiv\u00e1l\u00f3d\u00f3 gyullad\u00e1sos sejtek szerep\u00e9nek tanulm\u00e1nyoz\u00e1s\u00e1ra, szerep\u00fckre a toxicit\u00e1s kialak\u00edt\u00e1s\u00e1ban (1). C\u00e9ljaink k\u00f6zt szerepel az immunellen\u0151rz\u0151pont-g\u00e1tl\u00f3k kardiotoxikus mell\u00e9khat\u00e1s\u00e1nak kezel\u00e9se mellett olyan kombin\u00e1ci\u00f3s kezel\u00e9si elj\u00e1r\u00e1s kidolgoz\u00e1sa is, mely a tumorv\u00e1laszt nem befoly\u00e1solja, s\u0151t ak\u00e1r a tumorellenes hat\u00e1st fokozni tudja.<\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Projektek: <\/span><\/p>\n<ol>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Tumoros betegs\u00e9g \u00e9s sz\u00edvel\u00e9gtelens\u00e9g egym\u00e1sra gyakorolt hat\u00e1s\u00e1nak vizsg\u00e1lata<\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Tumorellenes ter\u00e1pia induk\u00e1lta sz\u00edvel\u00e9gtelens\u00e9g vizsg\u00e1lata \u00e9s befoly\u00e1sol\u00e1si lehet\u0151s\u00e9gei<\/span><\/p>\n<\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-13654 aligncenter\" src=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_szivelegtelenseg_gyogyszerek-400x236.png\" alt=\"\" width=\"647\" height=\"381\" srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_szivelegtelenseg_gyogyszerek-400x236.png 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_szivelegtelenseg_gyogyszerek-768x453.png 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_szivelegtelenseg_gyogyszerek-753x444.png 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/cardio-onko_szivelegtelenseg_gyogyszerek.png 1025w\" sizes=\"auto, (max-width: 647px) 100vw, 647px\" \/><\/span><\/p>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">A <\/span><span style=\"font-family: Times New Roman, serif\"><u><b>sz\u00edvel\u00e9gtelens\u00e9g<\/b><\/u><\/span><span style=\"font-family: Times New Roman, serif\"> \u00f6nmag\u00e1ban is<\/span><span style=\"font-family: Times New Roman, serif\"> nehezen befoly\u00e1solhat\u00f3, hosszan tart\u00f3 betegs\u00e9g, amely k\u00fcl\u00f6nb\u00f6z\u0151 okok miatt alakulhat ki. Sz\u00e1mtalan gy\u00f3gyszert haszn\u00e1lnak a kezel\u00e9s\u00e9re, azonban a betegek \u00e9letkil\u00e1t\u00e1sai rosszak, \u00edgy tov\u00e1bbi \u00faj \u00e9s hat\u00e9kony gy\u00f3gyszerekre van sz\u00fcks\u00e9g. Kutat\u00f3csoportunk \u00e1llatk\u00eds\u00e9rletek seg\u00edts\u00e9g\u00e9vel modellezi a sz\u00edvel\u00e9gtelens\u00e9get \u00e9s \u00faj gy\u00f3gyszerc\u00e9lpontokat keres.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Projektek:<\/span><\/p>\n<ol>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Gy\u00f3gyszer-induk\u00e1lta sz\u00edvizom diszfunkci\u00f3 modell \u00e9s farmakol\u00f3giai befoly\u00e1sol\u00e1si lehet\u0151s\u00e9geinek vizsg\u00e1lata<\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Nyom\u00e1st\u00falterhel\u00e9ses sz\u00edvel\u00e9gtelens\u00e9g modellben a sz\u00edvel\u00e9gtelens\u00e9g ter\u00e1pi\u00e1s lehet\u0151s\u00e9geinek vizsg\u00e1lata<\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Az korosod\u00e1s hat\u00e1sai a gy\u00f3gyszer-induk\u00e1lta sz\u00edvel\u00e9gtelens\u00e9gre<\/span><\/p>\n<\/li>\n<\/ol>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">Bizonyos sz\u00edvbetegs\u00e9gek (pl. a fent eml\u00edtett sz\u00edvel\u00e9gtelens\u00e9g is) m\u00e1r \u00f6nmag\u00e1ban egy onkog\u00e9n k\u00f6rnyezetet jelentenek, ami emeli a daganat megjelen\u00e9s\u00e9nek rizik\u00f3j\u00e1t. Az ilyen ford\u00edtott megk\u00f6zel\u00edt\u00e9st, ahol a sz\u00edvb\u0151l sz\u00e1rmaz\u00f3 faktoroknak a daganatra gyakorolt hat\u00e1s\u00e1t vizsg\u00e1ljuk, <\/span><span style=\"font-family: Times New Roman, serif\"><u><b>reverz onko-kardiol\u00f3gi\u00e1<\/b><\/u><\/span><span style=\"font-family: Times New Roman, serif\">nak h\u00edvjuk. Kutat\u00f3csoportunk vizsg\u00e1latokat v\u00e9gez annak kider\u00edt\u00e9se \u00e9rdek\u00e9ben, hogy a sz\u00edvel\u00e9gtelens\u00e9g vagy a sz\u00edvel\u00e9gtelens\u00e9g farmakoter\u00e1pi\u00e1ja fokozza-e a daganatk\u00e9pz\u0151d\u00e9s rizik\u00f3j\u00e1t, illetve a kialakul\u00f3 daganatok n\u00f6veked\u00e9se hogyan v\u00e1ltozik m\u00e1r fenn\u00e1ll\u00f3 sz\u00edvel\u00e9gtelens\u00e9g eset\u00e9n, \u00e9s ezek h\u00e1tter\u00e9ben milyen molekul\u00e1ris folyamatok \u00e1llhatnak. Ezen betegcsoportok sz\u00e1m\u00e1ra \u00faj kezel\u00e9si aj\u00e1nl\u00e1sokat k\u00edv\u00e1nunk megfogalmazni.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">Projektek:<\/span><\/p>\n<ol>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">A sz\u00edvel\u00e9gtelens\u00e9g hat\u00e1sa a tumorn\u00f6veked\u00e9sre<\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\">A sz\u00edvel\u00e9gtelens\u00e9g farmakoter\u00e1pi\u00e1j\u00e1nak hat\u00e1sa a tumorn\u00f6veked\u00e9sre<\/span><\/p>\n<\/li>\n<\/ol>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">Elsaj\u00e1t\u00edthat\u00f3 m\u00f3dszerek, technik\u00e1k:<\/span><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt\"><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>in vitro<\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"> sejtteny\u00e9szt\u00e9s \u00e9s k\u00eds\u00e9rleti rendszerek<\/span><\/span><\/span><\/li>\n<li><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><i>spektr\u00e1lis \u00e1raml\u00e1si citometria, immunfenotipiz\u00e1l\u00e1s<\/i><\/span><\/span><\/li>\n<li><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><i>munka k\u00eds\u00e9rleti \u00e1llatokkal<\/i><\/span><\/span><\/li>\n<li><span style=\"font-size: 14pt\"><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>in vivo <\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">tumormodellek l\u00e9trehoz\u00e1sa, vizsg\u00e1lata<\/span><\/span><\/span><\/li>\n<li><span style=\"font-size: 14pt\"><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">tumorn\u00f6veked\u00e9s monitoroz\u00e1sa k\u00e9palkot\u00f3 technik\u00e1k seg\u00edts\u00e9g\u00e9vel (tumorszkenner, ultrahang, <\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>in vivo <\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">fluoreszcencia \u00e9s biolumineszcencia alap\u00fa vizsg\u00e1latok)<\/span><\/span><\/span><\/li>\n<li><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">hisztol\u00f3giai technik\u00e1k, immunhisztok\u00e9mia, immunfluoreszcencia<\/span><\/span><\/li>\n<\/ul>\n<ol>\n<li>\n<p><span style=\"font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">A t\u00e9m\u00e1ban megjelent k\u00f6zlem\u00e9nyeink:Gergely TG, Kucsera D, T\u00f3th VE, et al. Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. <\/span><span style=\"font-family: Times New Roman, serif\"><i>Br J Pharmacol<\/i><\/span><span style=\"font-family: Times New Roman, serif\">. 2023;180(6):740-761. doi:10.1111\/bph.15984<\/span><\/span><\/p>\n<\/li>\n<\/ol>\n\n<\/div><h2 class=\"tabtitle\">Tagok<\/h2>\n<div class=\"tabcontent\">\n\n<p><strong>Munkacsoport-vezet\u0151:<\/strong><\/p>\n<p><a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=10509\">Dr. Varga Zolt\u00e1n, PhD<\/a><\/p>\n<p><strong>Kutat\u00f3k\/posztdoktorok:<\/strong><\/p>\n<p><a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=14782\">Dr. T\u00f3th Vikt\u00f3ria, PhD<\/a><br \/>\n<a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=21925\">Szab\u00f3 Lilla<\/a><br \/>\n<a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=19825\">Kov\u00e1cs Tam\u00e1s<\/a><br \/>\n<a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=22984\">Gelencs\u00e9rn\u00e9 Kulin Anna<\/a><br \/>\nDr. K\u00f6hler Zolt\u00e1n M\u00e1rton, PhD<\/p>\n<p><strong>PhD hallgat\u00f3k:<\/strong><\/p>\n<p><a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=18883\">Dr. Gergely Tam\u00e1s<\/a><br \/>\n<a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=18882\">Dr. Sayour Viktor Nabil<\/a><br \/>\n<a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=21920\">Dr. Jakab M\u00e1rk<\/a><br \/>\n<a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=21252\">Kocsis M\u00e1rton<\/a><br \/>\n<a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=21740\">Heged\u0171s Zsombor<\/a><br \/>\n<a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=22517\">Dr. Ayham Alhaddad<\/a><\/p>\n<p><strong>Asszisztensek:<\/strong><\/p>\n<p>Farkas Szabolcs<br \/>\n<a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=14239\">Kov\u00e1cs Andrea\u00a0<\/a><\/p>\n\n<\/div><h2 class=\"tabtitle\">K\u00e9pek<\/h2>\n<div class=\"tabcontent\">\n\n\r\n        [slb_exclude]\r\n        <div class=\"row galeria-wrapper mx-0 h-auto\">\r\n            <div class=\"col-9 pl-0 pr-2\">\r\n            <span class=\"gallery-item frame\">\r\n\t\t\t\t<div class=\"galeria-left-img\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8108-scaled.jpg\"><img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8108-scaled.jpg  \r\n                            alt=\"\" \r\n                            class=\"attachment-sote-gallery-big size-sote-gallery-big\" \r\n                            srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8108-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8108-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8108-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8108-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8108-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8108-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8108-203x135.jpg 203w\" ><\/a><\/div>\r\n            <\/span>\r\n\r\n            <\/div>\r\n\r\n\t\t\t<div class=\"col-3 pl-0 pr-0\">\r\n\t\t\t\t<div class=\"galeria-right-img d-flex justify-content-between flex-column h-100 w-100 px-0 mx-0 \">\r\n                <div class=\"galeria-box\">\r\n\t\t\t\t\t<h3 class=\"galeria-title\">Gal\u00e9ria<\/h3>\r\n\t\t\t\t\t<div class=\"galeria-subtitle\">\r\n\r\n\t\t\t\t\t\t<div class=\"galeria-page-counter\"><span>6<\/span>k\u00e9p<\/div>\r\n                    <\/div> <\/div>\r\n                    <span class=\"gallery-item frame d-none d-md-flex\">\r\n\t\t\t\t\t<div class=\"galeria-small-img mt-0\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7191-scaled.jpg\"><img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7191-scaled.jpg \r\n                                alt=\"\"  \r\n                                class=\"attachment-sote-gallery-small size-sote-gallery-small\" \r\n                                srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7191-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7191-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7191-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7191-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7191-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7191-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7191-203x135.jpg 203w\" ><\/a><\/div>\r\n                    <\/span>\r\n                    <span class=\"gallery-item frame d-none d-md-flex\">\r\n\t\t\t\t\t<div class=\"galeria-small-img mt-0\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7104-scaled.jpg\"><img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7104-scaled.jpg \r\n                                alt=\"\" \r\n                                class=\"attachment-sote-gallery-small size-sote-gallery-small\" \r\n                                srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7104-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7104-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7104-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7104-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7104-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7104-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7104-203x135.jpg 203w\" ><\/a><\/div>\r\n                    <\/span>\r\n\r\n                <\/div>\r\n\r\n            <\/div>\r\n\r\n            <span class=\"gallery-item\"><div class=\"hidden\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8078-scaled.jpg\">\r\n        <img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8078-scaled.jpg alt=\"\" class=\"attachment-sote-gallery-big size-sote-gallery-big\" srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8078-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8078-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8078-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8078-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8078-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8078-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8078-203x135.jpg 203w\" >\r\n        <\/a><\/div><\/span><span class=\"gallery-item\"><div class=\"hidden\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8082-scaled.jpg\">\r\n        <img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8082-scaled.jpg alt=\"\" class=\"attachment-sote-gallery-big size-sote-gallery-big\" srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8082-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8082-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8082-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8082-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8082-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8082-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8082-203x135.jpg 203w\" >\r\n        <\/a><\/div><\/span><span class=\"gallery-item\"><div class=\"hidden\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8074-scaled.jpg\">\r\n        <img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8074-scaled.jpg alt=\"\" class=\"attachment-sote-gallery-big size-sote-gallery-big\" srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8074-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8074-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8074-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8074-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8074-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8074-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL8074-203x135.jpg 203w\" >\r\n        <\/a><\/div><\/span>\r\n            <\/div>\r\n\r\n            [\/slb_exclude]\r\n\t\n<p>&nbsp;<\/p>\n<\/div><\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gyullad\u00e1sos \u00e9s immunol\u00f3giai folyamatok vizsg\u00e1lata kardiovaszkul\u00e1ris megbeteged\u00e9sekben A kr\u00f3nikus sz\u00edvel\u00e9gtelens\u00e9g progn\u00f3zisa a modern ter\u00e1pi\u00e1s eszk\u00f6z\u00f6k \u00e9s gy\u00f3gyszerek mellett is igen rossz, a betegek mintegy fele a diagn\u00f3zist k\u00f6vet\u0151 5 \u00e9ven bel\u00fcl meghal. A betegs\u00e9g kezel\u00e9se igen nagy terhet r\u00f3 az eg\u00e9szs\u00e9g\u00fcgyi rendszerekre. A sz\u00edvel\u00e9gtelens\u00e9g sz\u00e1mos okb\u00f3l j\u00f6het l\u00e9tre, de kialakul\u00e1sa sor\u00e1n a sz\u00edvizomzat szerkezete \u00e9s &hellip;<\/p>\n","protected":false},"author":102374,"featured_media":0,"parent":336,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-13521","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/13521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/users\/102374"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/comments?post=13521"}],"version-history":[{"count":10,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/13521\/revisions"}],"predecessor-version":[{"id":14880,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/13521\/revisions\/14880"}],"up":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/336"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/media?parent=13521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/categories?post=13521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/tags?post=13521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}